Dyne Therapeutics, Inc. (NASDAQ:DYN) Director Sells $474,045.00 in Stock

Dyne Therapeutics, Inc. (NASDAQ:DYN) Director Carlo Incerti sold 16,500 shares of the stock in a transaction on Monday, November 18th. The stock was sold at an average price of $28.73, for a total value of $474,045.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Dyne Therapeutics Price Performance

Shares of NASDAQ DYN opened at $29.34 on Tuesday. Dyne Therapeutics, Inc. has a 1-year low of $10.03 and a 1-year high of $47.45. The business has a fifty day moving average price of $32.42 and a 200 day moving average price of $35.26. The stock has a market capitalization of $2.99 billion, a P/E ratio of -8.24 and a beta of 1.10.

Dyne Therapeutics (NASDAQ:DYN) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.96) EPS for the quarter, missing the consensus estimate of ($0.71) by ($0.25). As a group, equities research analysts anticipate that Dyne Therapeutics, Inc. will post -3.39 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts recently commented on DYN shares. StockNews.com downgraded shares of Dyne Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, September 16th. Oppenheimer reaffirmed an “outperform” rating and set a $55.00 price target on shares of Dyne Therapeutics in a research note on Tuesday, September 3rd. JPMorgan Chase & Co. cut Dyne Therapeutics from an “overweight” rating to a “neutral” rating and dropped their price objective for the stock from $43.00 to $35.00 in a research note on Thursday, October 24th. Guggenheim lifted their target price on Dyne Therapeutics from $45.00 to $50.00 and gave the company a “buy” rating in a research report on Thursday, August 15th. Finally, Morgan Stanley increased their price target on Dyne Therapeutics from $48.00 to $52.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 14th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Dyne Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $51.40.

Institutional Investors Weigh In On Dyne Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Sei Investments Co. purchased a new stake in Dyne Therapeutics in the first quarter valued at about $693,000. Seven Eight Capital LP acquired a new position in shares of Dyne Therapeutics during the first quarter valued at about $516,000. Swiss National Bank raised its position in shares of Dyne Therapeutics by 41.5% in the 1st quarter. Swiss National Bank now owns 85,200 shares of the company’s stock valued at $2,419,000 after purchasing an additional 25,000 shares during the last quarter. Mutual of America Capital Management LLC acquired a new stake in Dyne Therapeutics in the 2nd quarter worth approximately $1,724,000. Finally, Vanguard Group Inc. boosted its stake in Dyne Therapeutics by 47.7% in the 1st quarter. Vanguard Group Inc. now owns 3,440,270 shares of the company’s stock worth $97,669,000 after purchasing an additional 1,110,629 shares in the last quarter. Hedge funds and other institutional investors own 96.68% of the company’s stock.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.